{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:10:33Z","timestamp":1793434233362,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"\n Importance<\/jats:title>\n Black women with hormone receptor\u2013positive breast cancer experience the greatest racial disparity in survival of all breast cancer subtypes. The relative contributions of social determinants of health and tumor biology to this disparity are uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the proportion of the Black-White disparity in breast cancer survival from estrogen receptor (ER)-positive, axillary node-negative breast cancer that is associated with adverse social determinants and high-risk tumor biology.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A retrospective mediation analysis of factors associated with the racial disparity in breast cancer death for cases diagnosed between 2004 and 2015 with follow-up through 2016 was carried out using the Surveillance, Epidemiology, and End Results (SEER) Oncotype registry. The study included women in the SEER-18 registry who were aged 18 years or older at diagnosis of a first primary invasive breast cancer tumor that was axillary node-negative and ER-positive, who were Black (Black), non-Hispanic White (White), and for whom the 21-gene breast recurrence score was available. Data analysis took place between March 4, 2021, and November 15, 2022.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Census tract socioeconomic disadvantage, insurance status, tumor characteristics including the recurrence score, and treatment variables.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Death due to breast cancer.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The analysis with 60\u202f137 women (mean [IQR] age 58.1 [50-66] years) included 5648 (9.4%) Black women and 54\u202f489 (90.6%) White women. With a median (IQR) follow-up time of 56 (32-86) months, the age-adjusted hazard ratio (HR) for breast cancer death among Black compared with White women was 1.82 (95% CI, 1.51-2.20). Neighborhood disadvantage and insurance status together mediated 19% of the disparity (mediated HR, 1.62; 95% CI, 1.31-2.00;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and tumor biological characteristics mediated 20% (mediated HR, 1.56; 95% CI, 1.28-1.90;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). A fully adjusted model that included all covariates accounted for 44% of the racial disparity (mediated HR, 1.38; 95% CI, 1.11-1.71;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Neighborhood disadvantage mediated 8% of the racial difference in the probability of a high-risk recurrence score (\n P<\/jats:italic>\n \u2009=\u2009.02).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study, racial differences in social determinants of health and indicators of aggressive tumor biology including a genomic biomarker were equally associated with the survival disparity in early-stage, ER-positive breast cancer among US women. Future research should examine more comprehensive measures of socioecological disadvantage, molecular mechanisms underlying aggressive tumor biology among Black women, and the role of ancestry-related genetic variants.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2022.7705","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T11:00:58Z","timestamp":1676545258000},"page":"536","source":"Crossref","is-referenced-by-count":50,"title":["Association of Social Determinants and Tumor Biology With Racial Disparity in Survival From Early-Stage, Hormone-Dependent Breast Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Kent F.","family":"Hoskins","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago"},{"name":"University of Illinois Cancer Center, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Calip","sequence":"additional","affiliation":[{"name":"University of Illinois Cancer Center, Chicago"},{"name":"Department of Pharmacy Systems, Outcomes and Policy, University of Illinois College of Pharmacy, Chicago"},{"name":"Flatiron Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Ching","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, University of Illinois College of Pharmacy, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiola","family":"Ibraheem","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago"},{"name":"University of Illinois Cancer Center, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana C.","family":"Danciu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago"},{"name":"University of Illinois Cancer Center, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth H.","family":"Rauscher","sequence":"additional","affiliation":[{"name":"University of Illinois Cancer Center, Chicago"},{"name":"Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"coi220097r1","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/1097-0142(19851001)56:7<1704::AID-CNCR2820560740>3.0.CO;2-L","article-title":"Race-related differences in breast cancer patients. Results of the 1982 national survey of breast cancer by the American College of Surgeons.","volume":"56","author":"Natarajan","year":"1985","journal-title":"Cancer"},{"issue":"3","key":"coi220097r3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3322\/caac.21718","article-title":"Cancer statistics for African American\/Black People 2022.","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"coi220097r4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3322\/caac.21703","article-title":"American Cancer Society\u2019s report on the status of cancer disparities in the United States, 2021.","volume":"72","author":"Islami","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"coi220097r5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2014.17322","article-title":"Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States.","volume":"313","author":"Iqbal","year":"2015","journal-title":"JAMA"},{"issue":"24","key":"coi220097r6","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1158\/1078-0432.CCR-10-1533","article-title":"Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.","volume":"16","author":"O\u2019Brien","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"coi220097r7","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/jnci\/djr543","article-title":"Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.","volume":"104","author":"Sparano","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"coi220097r8","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1200\/JCO.2014.57.1349","article-title":"Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors.","volume":"33","author":"Warner","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi220097r9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10549-017-4166-z","article-title":"Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities.","volume":"163","author":"Rauscher","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"coi220097r10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/1055-9965.EPI-20-1291","article-title":"Racial\/ethnic disparities in survival after breast cancer diagnosis by estrogen and progesterone receptor status: a pooled analysis.","volume":"30","author":"John","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"coi220097r11","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"coi220097r12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamaoncol.2020.7320","article-title":"Association of race\/ethnicity and the 21-gene recurrence score with breast cancer-specific mortality among US women.","volume":"7","author":"Hoskins","year":"2021","journal-title":"JAMA Oncol"},{"issue":"9","key":"coi220097r13","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2105\/AJPH.2006.102525","article-title":"Approaching health disparities from a population perspective: the National Institutes of Health Centers for Population Health and Health Disparities.","volume":"98","author":"Warnecke","year":"2008","journal-title":"Am J Public Health"},{"issue":"14","key":"coi220097r14","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1002\/cncr.29935","article-title":"Understanding and effectively addressing breast cancer in African American women: unpacking the social context.","volume":"122","author":"Williams","year":"2016","journal-title":"Cancer"},{"issue":"13","key":"coi220097r15","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1200\/JCO.21.02004","article-title":"Linking structural racism and discrimination and breast cancer outcomes: a social genomics approach.","volume":"40","author":"Carlos","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi220097r16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1200\/JCO.2017.74.5448","article-title":"Racial differences in 21-gene recurrence scores among patients with hormone receptor-positive, node-negative breast cancer.","volume":"36","author":"Holowatyj","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi220097r17","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cncr.26180","article-title":"21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome.","volume":"118","author":"Lund","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"coi220097r18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10549-019-05340-7","article-title":"Social determinants of breast cancer risk, stage, and survival.","volume":"177","author":"Coughlin","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"coi220097r19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12672-018-0325-x","article-title":"Urban neighborhood and residential factors associated with breast cancer in African American women: a systematic review.","volume":"9","author":"Smith","year":"2018","journal-title":"Horm Cancer"},{"issue":"1","key":"coi220097r20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2017.74.2049","article-title":"Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional, and neighborhood characteristics.","volume":"36","author":"Ellis","year":"2018","journal-title":"J Clin Oncol"},{"issue":"49","key":"coi220097r21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/jncimonographs\/lgu020","article-title":"Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) Registries.","volume":"2014","author":"Kish","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"4","key":"coi220097r22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1001\/jamaoncol.2021.7656","article-title":"Assessment of racial disparity in survival outcomes for early hormone receptor-positive breast cancer after adjusting for insurance status and neighborhood deprivation: a post hoc analysis of a randomized clinical trial.","volume":"8","author":"Sadigh","year":"2022","journal-title":"JAMA Oncol"},{"issue":"24","key":"coi220097r23","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1002\/cncr.33861","article-title":"Individual- and neighborhood-level socioeconomic status and risk of aggressive breast cancer subtypes in a pooled cohort of women from Kaiser Permanente Northern California.","volume":"127","author":"Aoki","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"coi220097r24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1158\/1055-9965.EPI-20-1055","article-title":"Neighborhood social environmental factors and breast cancer subtypes among Black women.","volume":"30","author":"Qin","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"17","key":"coi220097r25","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1002\/cncr.32956","article-title":"Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.","volume":"126","author":"Ibraheem","year":"2020","journal-title":"Cancer"},{"issue":"8","key":"coi220097r27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.7326\/0003-4819-125-8-199610150-00008","article-title":"The medicalization of race: scientific legitimization of a flawed social construct.","volume":"125","author":"Witzig","year":"1996","journal-title":"Ann Intern Med"},{"issue":"5","key":"coi220097r28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMms2029562","article-title":"Race and genetic ancestry in medicine - a time for reckoning with racism.","volume":"384","author":"Borrell","year":"2021","journal-title":"N Engl J Med"},{"key":"coi220097r29","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1038\/npjbcancer.2016.17","article-title":"Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.","volume":"2","author":"Petkov","year":"2016","journal-title":"NPJ Breast Cancer"},{"issue":"21","key":"coi220097r31","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer.","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"coi220097r32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"coi220097r33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jamaoncol.2019.4794","article-title":"Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial.","volume":"6","author":"Sparano","year":"2020","journal-title":"JAMA Oncol"},{"key":"coi220097r34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12874-016-0130-6","article-title":"Mechanisms and mediation in survival analysis: towards an integrated analytical framework.","volume":"16","author":"Pratschke","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"coi220097r35","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3389\/fpsyg.2019.00740","article-title":"Evaluating a method to estimate mediation effects with discrete-time survival outcomes.","volume":"10","author":"Fairchild","year":"2019","journal-title":"Front Psychol"},{"issue":"2","key":"coi220097r36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.rssm.2010.12.005","article-title":"Decomposing primary and secondary effects: a new decomposition method.","volume":"29","author":"Karlson","year":"2011","journal-title":"Res Soc Stratification Mobility"},{"issue":"1","key":"coi220097r37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0049124187016001006","article-title":"Direct and indirect effects in linear structural equation models.","volume":"16","author":"Sobel","year":"1987","journal-title":"Sociol Methods Res"},{"issue":"4","key":"coi220097r38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/jnci\/djaa148","article-title":"Race, ethnicity, and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial.","volume":"113","author":"Albain","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"coi220097r39","article-title":"Impact of genetic ancestry on outcomes in ECOG-ACRIN-E5103.","volume":"2017","author":"Schneider","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"coi220097r40","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation.","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"15","key":"coi220097r41","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.2021.39.15_suppl.1009","article-title":"Disparities within luminal breast cancer: Clinical and molecular features of African American and non-Hispanic white patients.","volume":"39","author":"Hoskins","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi220097r42","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/cncr.33290","article-title":"Weighing the influence of race and obesity on outcomes in patients with early-stage breast cancer.","volume":"127","author":"Taylor","year":"2021","journal-title":"Cancer"},{"issue":"11","key":"coi220097r43","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/cncr.34173","article-title":"Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103).","volume":"128","author":"Ballinger","year":"2022","journal-title":"Cancer"},{"issue":"22","key":"coi220097r44","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1002\/cncr.33121","article-title":"Breast cancer treatment delays by socioeconomic and health care access latent classes in Black and White women.","volume":"126","author":"Emerson","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"coi220097r45","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/MLR.0000000000000073","article-title":"Comparison of SEER treatment data with Medicare claims.","volume":"54","author":"Noone","year":"2016","journal-title":"Med Care"},{"issue":"14","key":"coi220097r46","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/jnci\/djp176","article-title":"Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis.","volume":"101","author":"Menashe","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"coi220097r2","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. Accessed May 24, 2022. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"key":"coi220097r26","unstructured":"National Comprehensive Cancer Network. Breast Cancer (Version 3.2022). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed May 24, 2022."},{"key":"coi220097r30","unstructured":"Surveillance? E, Results? E. (SEER) Program (http:\/\/www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs (Excl AK) Custom Data Malignant Breast (with Oncotype DX and Additional Treatment Fields), Nov 2018 Sub (2004-2015) - Linked To County Attributes - Total U.S., 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2801589\/jamaoncology_hoskins_2023_oi_220097_1681755652.16355.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T12:39:17Z","timestamp":1681994357000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2801589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.7705","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,1]]}}}